Oxytocin vs PT-141 (Bremelanotide)
A side-by-side research comparison of Oxytocin and PT-141 (Bremelanotide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Oxytocin | PT-141 (Bremelanotide) |
|---|---|---|
| Full name | Oxytocin (OXT) | Bremelanotide (PT-141 / Vyleesi) |
| Category | Sexual Health | Sexual Health |
| Status | FDA Approved | FDA Approved |
| Mechanism | Binds OXTR in social cognition brain regions (amygdala, nucleus accumbens) and reproductive organs. Modulates serotonin and dopamine in reward circuits. | MC4R agonist in hypothalamus activating central sexual arousal pathways. Increases dopaminergic signaling independent of vascular mechanisms. |
| Molecular weight | 1,007 Da | 1,025 Da |
| Half-life | 3-5 min (IV) / 20-30 min (intranasal) | 2.7 hours |
| Bioavailability | Low (oral), Moderate (intranasal ~2-5%) | High (SubQ) |
| Typical dose | 20-40 IU intranasal | 1.75 mg |
| Frequency | As needed or daily | As needed, ~45 min before activity |
| Route | Intranasal or IV (obstetric) | Subcutaneous injection |
Oxytocin reported benefits
- Enhanced social bonding
- Improved intimacy
- Anxiolytic effects
- Pain modulation
- Post-orgasmic well-being
PT-141 (Bremelanotide) reported benefits
- Increased sexual desire
- Central arousal mechanism
- Works both sexes (research)
- Non-vascular
- Rapid onset
Related comparisons
Research and educational reference only. Not medical advice.